Desmoplasia: Not always a bad thing

Histopathology

Volumn 58, Issue 5, 2011, Pages 643-659

  Abbas, Ossama ^a   Mahalingam, Meera ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Desmoplasia; Extracellular matrix; Fibroblasts

Indexed keywords

BENIGN TUMOR; DESMOPLASIA; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; PRIORITY JOURNAL; REVIEW; TUMOR DIAGNOSIS; TUMOR IMMUNITY;

ANIMALS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; NEOPLASMS; SKIN NEOPLASMS; STROMAL CELLS;

EID: 79954487861     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03617.x     Document Type: Review

References (107)

1. Barr RJ, Morales RV, Graham JH. Desmoplastic nevus: a distinct histologic variant of mixed spindle cell and epithelioid cell nevus. Cancer 1980; 46; 557-564.
2. Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod. Pathol. 2006; 19; S41-S70.
3. Ferrara G, Brasiello M, Annese P et al. Desmoplastic nevus: clinicopathologic keynotes. Am. J. Dermatopathol. 2009; 31; 718-722.
4. Huber MA, Kraut N, Park JE et al. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J. Invest. Dermatol. 2003; 120; 182-188.
5. Kawashiri S, Tanaka A, Noguchi N et al. Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck 2009; 31; 1346-1353.
6. Koperek O, Scheuba C, Puri C et al. Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma. Int. J. Oncol. 2007; 31; 59-67.
7. Dolznig H, Schweifer N, Puri C et al. Characterization of cancer stroma markers: insilico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 2005; 5; 10.
8. Huber MA, Kraut N, Schweifer N et al. Expression of stromal cell markers in distinct compartments of human skin cancers. J. Cutan. Pathol. 2006; 33; 145-155.
9. Longacre TA, Egbert BM, Rouse RV. Desmoplastic and spindle cell melanoma. An immunohistochemical study. Am. J. Surg. Pathol. 1996; 20; 1489-1500.
10. Iacobuzio-Donahue CA, Argani P, Hempen PM et al. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res. 2002; 62; 5351-5357.
11. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am. J. Pathol. 2002; 160; 91-99.
12. Tuxhorn JA, Ayala GE, Smith MJ et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 2002; 8; 2912-2923.
13. Brantsch KD, Meisner C, Schönfisch B et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008; 9; 713-720.
14. Hasebe T, Mukai K, Ishihara K, Kaneko A, Shimosato Y. Sebaceous gland and sweat gland carcinomas of the skin. Clinicopathological study and significance of c-erbB-2 oncoprotein expression. Acta Pathol. Jpn. 1992; 42; 585-594.
15. Martín JM, Jordá E, Monteagudo C et al. Desmoplastic giant congenital nevus with progressive depigmentation. J. Am. Acad. Dermatol. 2007; 56; S10-S14.
16. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 2000; 6; 324-329.
17. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411; 375-379.
18. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002; 70; 486-497.
19. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol. 2002; 3; 35-43.
20. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986; 315; 1650-1659.
21. Barr LC, Carter RL, Davies AJ. Encapsulation of tumours as a modified wound healing response. Lancet 1988; 2; 135-137.
22. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008; 9; 628-638.
23. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004; 4; 839-849.
24. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim. Biophys. Acta 2009; 1796; 293-308.
25. Singh S, Barrett J, Sakata K, Tozer RG, Singh G. ETS proteins and MMPs: partners in invasion and metastasis. Curr. Drug Targets 2002; 3; 359-367.
26. Myers E, Hill AD, Kelly G et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer Res. 2005; 11; 2111-2122.
27. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006; 6; 392-401.
28. Liu YJ, Yan PS, Li J, Jia JF. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J. Gastroenterol. 2005; 11; 6601-6606.
29. Pozdnyakova O, Hoang MM, Dresser KA, Mahalingam M. Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma. Arch. Pathol. Lab. Med. 2009; 133; 1285-1290.
30. Lee SB, Schramme A, Doberstein K et al. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J. Invest. Dermatol. 2010; 130; 763-773.
31. Walsh NM, Roberts JT, Orr W, Simon GT. Desmoplastic malignant melanoma. A clinicopathological study of 14 cases. Arch. Pathol. Lab. Med. 1988; 112; 922-927.
32. Valensi QJ. Desmoplastic malignant melanoma. A light and electron microscopic study of two cases. Cancer 1979; 43; 1148-1155.
33. Valensi QJ. Desmoplastic malignant melanoma. Study of a case by light and electronmicroscopy. J. Dermatol. Surg. Oncol. 1979; 5; 31-35.
34. Busam KJ, Zhao H, Coit DG et al. Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. J. Invest. Dermatol. 2005; 124; 412-418.
35. Michal M, Kerekes Z, Kinkor Z, Ondriás F, Pizinger K. Desmoplastic cellular blue nevus. Am. J. Dermatopathol. 1995; 17; 230-235.
36. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 1999; 274; 36505-36512.
37. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl Acad. Sci. USA 1990; 87; 7235-7239.
38. Kojc N, Zidar N, Vodopivec B, Gale N. Expression of CD34, alpha-smooth muscle actin, and transforming growth factor beta1 in squamous intraepithelial lesions and squamous cell carcinoma of the larynx and hypopharynx. Hum. Pathol. 2005; 36; 16-21.
39. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp. Dermatol. 2003; 12; 109-125.
40. Vosseler S, Lederle W, Airola K, Obermueller E, Fusenig NE, Mueller MM. Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. Int. J. Cancer 2009; 125; 2296-2306.
41. Tsukifuji R, Tagawa K, Hatamochi A, Shinkai H. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br. J. Cancer 1999; 80; 1087-1091.
42. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 2009; 85; 314-323.
43. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006; 6; 506-520.
44. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-beta and the tumor microenvironment. J. Cell. Biochem. 2007; 101; 851-861.
45. Reed RJ, Ichinose H, Clark WH Jr, Mihm MC Jr. Common and uncommon melanocytic nevi and borderline melanomas. Semin. Oncol. 1975; 2; 119-147.
46. Mackie RM, Doherty VR. The desmoplastic melanocytic naevus: a distinct histological entity. Histopathology 1992; 20; 207-211.
47. Harris G, Shea CR, Horenstein MG, Reed JA, Burchette JL Jr, Prieto VG. Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma. Am. J. Surg. Pathol. 1999; 23; 786-794.
48. Paniago-Pereira C, Maize JC, Ackerman AB. Nevus of large spindle and/or epithelioid cells (Spitz's nevus). Arch. Dermatol. 1978; 114; 1811-1823.
49. Requena C, Requena L, Kutzner H, Sánchez Yus E. Spitz nevus: a clinicopathological study of 349 cases. Am. J. Dermatopathol. 2009; 31; 107-116.
50. Ferrara G, Argenziano G, Soyer HP et al. The spectrum of Spitz nevi: a clinicopathologic study of 83 cases. Arch. Dermatol. 2005; 141; 1381-1387.
51. Lazzaro B, Rebers A, Herlyn M et al. Immunophenotyping of compound and Spitz nevi and vertical growth phase melanomas using a panel of monoclonal antibodies reactive in paraffin sections. J. Invest. Dermatol. 1993; 100; 313S-317S.
52. Bergman R, Azzam H, Sprecher E et al. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J. Am. Acad. Dermatol. 2000; 42; 496-500.
53. Rongioletti F, Innocenzi D. Sclerosing 'mucinous' blue naevus. Br. J. Dermatol. 2003; 148; 1250-1252.
54. Hogan DJ, Murphy F, Bremner RM. Spontaneous resolution of a giant congenital melanocytic nevus. Pediatr. Dermatol. 1988; 5; 170-172.
55. Ruiz-Maldonado R, Orozco-Covarrubias L, Ridaura-Sanz C et al. Desmoplastic hairless hypopigmented naevus: a variant of giant congenital melanocytic naevus. Br. J. Dermatol. 2003; 148; 1253-1257.
56. Bushby SA, Rajan NJ, Shehade SA. Spontaneous resolution of a giant melanocytic naevus involving a desmoplastic process. Br. J. Dermatol. 2005; 153; 13-19.
57. Pattee SF, Hansen RC, Bangert JL, Joganic EF. Giant congenital nevus with progressive sclerodermiform reaction in a newborn. Pediatr. Dermatol. 2001; 18; 321-324.
58. Brownstein MH, Shapiro L. Desmoplastic trichoepithelioma. Cancer 1977; 40; 2979-2986.
59. Macdonald DM, Jones EW, Marks R. Sclerosing epithelial hamartoma. Clin. Exp. Dermatol. 1977; 2; 153-160.
60. Dervan PA, O'Hegarty M, O'Loughlin S, Corrigan T. Solitary familial desmoplastic trichoepithelioma. A study by conventional and electron microscopy. Am. J. Dermatopathol. 1985; 7; 277-282.
61. Costache M, Bresch M, Böer A. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: a critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology 2008; 52; 865-876.
62. Hunt SJ, Kilzer B, Santa Cruz DJ. Desmoplastic trichilemmoma: histologic variant resembling invasive carcinoma. J. Cutan. Pathol. 1990; 17; 45-52.
63. Tellechea O, Reis JP, Baptista AP. Desmoplastic trichilemmoma. Am. J. Dermatopathol. 1992; 14; 107-114.
64. Illueca C, Monteagudo C, Revert A, Llombart-Bosch A. Diagnostic value of CD34 immunostaining in desmoplastic trichilemmoma. J. Cutan. Pathol. 1998; 25; 435-439.
65. Tardío JC. CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions. J. Cutan. Pathol. 2009; 36; 89-102.
66. Cribier B, Grosshans E. Tumor of the follicular infundibulum: a clinicopathologic study. J. Am. Acad. Dermatol. 1995; 33; 979-984.
67. Mahalingam M, Bhawan J, Finn R, Stefanato CM. Tumor of the follicular infundibulum with sebaceous differentiation. J. Cutan. Pathol. 2001; 28; 314-317.
68. Abbas O, Mahalingam M. Tumor of the follicular infundibulum: an epidermal reaction pattern? Am. J. Dermatopathol. 2009; 31; 626-633.
69. Starink TM, Meijer CJ, Brownstein MH. The cutaneous pathology of Cowden's disease: new findings. J. Cutan. Pathol. 1985; 12; 83-93.
70. Rapini RP. Golitz LE: Sclerotic fibromas of the skin. J. Am. Acad. Dermatol. 1989; 20; 266-271.
71. Wilk M, Kaiser HW, Steen KH, Kreysel HW. Sclerotic fibroma. Hautarzt 1995; 46; 413-416.
72. Lisovsky M, Hoang MP, Dresser KA, Kapur P, Bhawan J, Mahalingam M. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Mod. Pathol. 2008; 21; 31-38.
73. Huang HY, Sung MT, Eng HL, Huang CC, Huang WT, Chen WJ. Superficial collagenous fibroma: immunohistochemical, ultrastructural, and flow cytometric study of three cases, including one pemphigus vulgaris patient with a dermal mass. APMIS 2002; 110; 283-289.
74. Evans HL. Desmoplastic fibroblastoma. Am. J. Surg. Pathol. 1995; 19; 1077-1081.
75. Junkins-Hopkins JM, Johnson WC. Desmoplastic fibroblastoma. J. Cutan. Pathol. 1998; 25; 450-454.
76. Takahara M, Ichikawa R, Oda Y et al. Desmoplastic fibroblastoma: a case presenting as a protruding nodule in the dermis. J. Cutan. Pathol. 2008; 35; 70-73.
77. Pulitzer D, Reed R. Nerve-sheath myxoma (perineurial myxoma). Am. J. Dermatopathol. 1985; 7; 409-421.
78. Mahalingam M, Alter J, Bhawan J. Multiple cellular neurothekeomas-a case report and review on the role of immunohistochemistry as a histologic adjunct. J. Cutan. Pathol. 2006; 33; 51-56.
79. Hornick J, Fletcher C. Cellular neurothekeoma: detailed characterization in a series of 133 cases. Am. J. Surg. Pathol. 2007; 31; 329-340.
80. Zedek DC, White WL, McCalmont TH. Desmoplastic cellular neurothekeoma: clinicopathological analysis of twelve cases. J. Cutan. Pathol. 2009; 36; 1185-1190.
81. Fetsch JF, Miettinen M. Sclerosing perineurioma: a clinicopathologic study of 19 cases of a distinctive soft tissue lesion with a predilection for the fingers and palms of young adults. Am. J. Surg. Pathol. 1997; 21; 1433-1442.
82. Rubin AI, Yassaee M, Johnson W, Elenitsas R, Zaladonis J Jr, Seykora JT. Multiple cutaneous sclerosing perineuriomas: an extensive presentation with involvement of the bilateral upper extremities. J. Cutan. Pathol. 2009; 36; 60-65.
83. Hunt SJ, Santa Cruz DJ, Barr RJ. Microvenular hemangioma. J. Cutan. Pathol. 1991; 18; 235-240.
84. Aloi F, Tomasini C, Pippione M. Microvenular hemangioma. Am. J. Dermatopathol. 1993; 15; 534-538.
85. George E, McClain SE, Slingluff CL, Polissar NL, Patterson JW. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J. Cutan. Pathol. 2009; 36; 425-432.
86. Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br. J. Dermatol. 2005; 152; 673-678.
87. de AlmeidaLS, Requena L, Rütten A et al. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. Am. J. Dermatopathol. 2008; 30; 207-215.
88. Radfar A, Stefanato CM, Ghosn S, Bhawan J. NGFR-positive desmoplastic melanomas with focal or absent S-100 staining: further evidence supporting the use of both NGFR and S-100 as a primary immunohistochemical panel for the diagnosis of desmoplastic melanomas. Am. J. Dermatopathol. 2006; 28; 162-167.
89. Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer 1997; 79; 915-919.
90. Seal A, Zloty D. Desmoplastic squamous cell carcinoma: case presentation and literature review. J. Cutan. Med. Surg. 2008; 12; 243-245.
91. Morgan MB, Purohit C, Anglin TR. Immunohistochemical distinction of cutaneous spindle cell carcinoma. Am. J. Dermatopathol. 2008; 30; 228-232.
92. Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J. Cutan. Pathol. 2006; 33; 413-417.
93. Petter G, Haustein UF. Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. Dermatol. Surg. 2000; 26; 521-530.
94. Litzow TJ, Perry HO, Soderstrom CW. Morpheaform basal cell carcinoma. Am. J. Surg. 1968; 116; 499-505.
95. Carra RA, Taibjeeb SM, Sanders DSA. Basaloid skin tumours: basal cell carcinoma. Curr. Diagn. Pathol. 2007; 13; 252-272.
96. Jones M, Bresch M, Alvarez D, Böer A. Keloidal basal cell carcinoma: not a distinctive clinicopathological entity. Br. J. Dermatol. 2009; 160; 127-131.
97. Goldstein DJ, Barr RJ, Santa Cruz DJ. Microcystic adnexal carcinoma: a distinct clinicopathologic entity. Cancer 1982; 50; 566-572.
98. Sebastien TS, Nelson BR, Lowe L, Baker S, Johnson TM. Microcystic adnexal carcinoma. J. Am. Acad. Dermatol. 1993; 29; 840-845.
99. Hoang MP, Dresser KA, Kapur P et al. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod. Pathol. 2008; 21; 178-185.
100. Carvalho J, Fullen D, Lowe L, Su L, Ma L. The expression of CD23 in cutaneous non-lymphoid neoplasms. J. Cutan. Pathol. 2007; 34; 693-698.
101. Karroum JE, Zappi EG, Cockerell CJ. Sclerotic primary cutaneous leiomyosarcoma. Am. J. Dermatopathol. 1995; 17; 292-296.
102. Diaz-Cascajo C, Borghi S, Weyers W. Desmoplastic leiomyosarcoma of the skin. Am. J. Dermatopathol. 2000; 22; 251-255.
103. Choy C, Cooper A, Kossard S. Primary cutaneous diffuse leiomyosarcoma with desmoplasia. Australas. J. Dermatol. 2006; 47; 291-295.
104. Berzal-Cantalejo F, Sabater-Marco V, Pérez-Vallés A, Martorell-Cebollada M. Desmoplastic cutaneous leiomyosarcoma: case report and review of the literature. J. Cutan. Pathol. 2006; 33; 29-31.
105. Kaneishi NK, Cockerell CJ. Histologic differentiation of desmoplastic melanoma from cicatrices. Am. J. Dermatopathol. 1998; 20; 128-134.
106. Saeed S, Keehn CA, Morgan MB. Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal. J. Cutan. Pathol. 2004; 31; 419-430.
107. Sariya D, Ruth K, Adams-McDonnell R et al. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch. Dermatol. 2007; 143; 613-620.